STOCK TITAN

Jasper Therapeutics Q3 net loss widens to $144M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Jasper Therapeutics reported third-quarter 2026 results and a clinical-program update. Revenue for the quarter ended September 30, 2026 was $8.0 million, compared with — in the year-earlier quarter. Total operating expenses were $152.173 million, including $129.494 million in acquired in-process research and development expense; net loss was $144.455 million, versus $18.736 million a year earlier. Cash and cash equivalents were $135.349 million at September 30, 2026, compared with $28.692 million at December 31, 2025.

Following its acquisition of Kira Pharmaceuticals, Jasper completed enrollment in the first cohort of its Phase 2 renal basket study of vensobafusp alfa in patients with IgA nephropathy (IgAN), and enrolled the first patient with immune complex membranoproliferative glomerulonephritis (IC-MPGN). The company also began an expansion cohort for focal segmental glomerulosclerosis (FSGS); its first patient is expected to be dosed in Q1 2027. Interim IgAN cohort data are expected in Q4 2026.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 1 point

How the balance works

Positive

  • None.

Negative

  • Major pointQuarterly net loss was $144.455 million, versus $18.736 million a year earlier.

Filing Explained

At September 30, Jasper reported $263,502 thousand of non-voting redeemable convertible preferred stock; conversion requires stockholder approval, and the release warns that failure to obtain approval could create cash-settlement obligations.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Revenue $8.0 million Three months ended September 30, 2026; 2025 comparative is —.
Total operating expenses $152.173 million Three months ended September 30, 2026, compared with $19.166 million in 2025.
Net loss $144.455 million Three months ended September 30, 2026, compared with $18.736 million in 2025.
Acquired in-process research and development expense $129.494 million Three months ended September 30, 2026.
Cash and cash equivalents $135.349 million As of September 30, 2026; $28.692 million as of December 31, 2025.
Non-voting redeemable convertible preferred stock $263.502 million Balance sheet at September 30, 2026.
renal basket study medical
"Phase 2 renal basket study evaluating vensobafusp alfa"
vensobafusp alfa medical
"study evaluating vensobafusp alfa (KP104) in patients with IgA nephropathy"
IgA nephropathy medical
"patients with IgA nephropathy (IgAN)"
A kidney disease caused when deposits of the antibody called IgA collect in the tiny filters of the kidney, gradually reducing their ability to clear waste — like grit building up in a water filter. It matters to investors because it creates demand for diagnostics, drugs and long‑term care, drives clinical trial activity and regulatory decisions, and can influence the financial outlook of companies in pharma, biotech, medical devices and health insurance.
immune complex membranoproliferative glomerulonephritis medical
"patient with immune complex membranoproliferative glomerulonephritis (IC-MPGN)"
A type of kidney inflammation where immune molecules form clumps that stick in and damage the tiny filters in the kidney, causing blood and protein to leak into urine and reducing the organ’s ability to clean the blood. Investors should care because prevalence, treatment options, and clinical trial results for therapies can materially affect healthcare costs, drug company valuations, regulatory decisions, and potential market opportunities in nephrology.
focal segmental glomerulosclerosis medical
"expansion cohort in patients with focal segmental glomerulosclerosis (FSGS)"
Focal segmental glomerulosclerosis is a chronic kidney disease in which some of the tiny filters in the kidneys (glomeruli) become scarred in parts, reducing the organ’s ability to remove waste and control fluid balance. For investors, it matters because the condition can drive sustained demand for specialized drugs, diagnostic tests, and treatment services, influence healthcare spending and reimbursement dynamics, and affect the commercial prospects of companies developing therapies or diagnostics for rare kidney disorders.
acquired in-process research and development financial
"Acquired in-process research and development expense"
Acquired in-process research and development is the unfinished scientific work and product programs a company buys from another firm as part of a deal — think of it as buying an unfinished prototype and the team working on it. Investors care because the buyer is paying for future potential that may never materialize; that payment often shows up as a large one-time cost and signals higher risk and reward tied to future products rather than current sales.
Revenue $8.0 million Compared with — for the three months ended September 30, 2025
Total operating expenses $152.173 million Compared with $19.166 million for the three months ended September 30, 2025
Net loss $144.455 million Compared with $18.736 million for the three months ended September 30, 2025
Cash and cash equivalents $135.349 million Compared with $28.692 million at December 31, 2025

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Jasper Therapeutics (JSPR)’s Q3 2026 revenue and net loss?

Jasper reported $8.0 million in revenue and a $144.455 million net loss for the three months ended September 30, 2026. Revenue was shown as a dash for the 2025 quarter, and the year-earlier net loss was $18.736 million.

When does Jasper Therapeutics expect interim IgAN data?

Jasper said it looks forward to presenting interim data from the IgAN cohort in the fourth quarter of 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001788028 0001788028 2026-11-16 2026-11-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): November 16, 2026

 

JASPER THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   001-39138   84-2984849
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

2200 Bridge Pkwy Suite #102
Redwood City, California 94065

(Address of Principal Executive Offices) (Zip Code)

 

(650) 549-1400

Registrant’s telephone number, including area code

 

N/A

(Former Name, or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

(Title of each class)   (Trading Symbol)   (Name of exchange on which registered)
Voting Common Stock, par value $0.0001 per share   JSPR   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On November 16, 2026, Jasper Therapeutics, Inc. issued a press release reporting its financial results for the quarter ended September 30, 2026 and providing a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

In accordance with General Instructions B.2 of Form 8-K, the information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is being furnished under Item 2.02 and Item 9.01 of Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press Release, dated November 16, 2026. 
104   Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 16, 2026 JASPER THERAPEUTICS, INC.
   
  By: /s/ Jeet Mahal
  Name: Jeet Mahal
  Title: Chief Executive Officer

 

2

 

Exhibit 99.1

 

 

Jasper Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

 

REDWOOD CITY, Calif., November 16, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported results for the fiscal quarter ended September 30, 2026, and provided a corporate update.

 

“We have made progress advancing our development programs in recent months following our acquisition of Kira Pharmaceuticals, highlighted by the recent completion of enrollment in the first cohort of our Phase 2 renal basket study evaluating vensobafusp alfa (KP104) in patients with IgA nephropathy (IgAN),” said Jeet Mahal, President and Chief Executive Officer of Jasper. “In addition, we enrolled the first patient with immune complex membranoproliferative glomerulonephritis (IC-MPGN) in the renal basket study and commenced an expansion cohort in patients with focal segmental glomerulosclerosis (FSGS), with the first patient expected to be dosed in the first quarter of 2027. We believe that the bifunctional ability of vensobafusp alfa to inhibit both the alternative and terminal complement pathways may provide the potential for differentiated onset and efficacy in complement driven diseases, and we look forward to presenting interim data from the IgAN cohort in the fourth quarter of 2026 and additional updates from our pipeline programs in 2027.”

 

Third Quarter 2026 and Recent Highlights

 

●Completed enrollment in first cohort of Phase 2 renal basket study evaluating vensobafusp alfa in IgA nephropathy.

 

○Jasper expects to report interim IgAN data from Stage 1 of the renal basket study in the fourth quarter of 2026 and updated data in the first quarter of 2027.

 

●Announced the opening of an expansion cohort in the renal basket study evaluating vensobafusp alfa in patients with FSGS, with first patients expected to be dosed in first quarter 2027.

 

●Commenced patient enrollment in the C3 glomerulopathy (C3G)/IC-MPGN cohort of the renal basket study.

 

○First IC-MPGN patient dosed.

 

○IC-MPGN is a complement-mediated glomerulonephritis characterized by immune complex deposition, complement activation, and downstream alternative pathway amplification. Given the overlap with C3G in complement biology, IC-MPGN is being evaluated together with C3G in a rare complement-mediated kidney disease cohort

 

●Jasper is completing a Phase 1/2 case control study evaluating briquilimab as a conditioning agent for SCID patients receiving hematopoietic stem cell transplant.

 

○The company expects to present initial data from the study in the fourth quarter of 2026.

 

●In July 2026, Jasper completed the acquisition of Kira Pharmaceuticals (“Kira”), a Cayman limited company that was engaged in the design of complement therapies to treat immune-mediated diseases, in an all-stock transaction.

 

○Concurrently with the acquisition, Jasper entered into a securities purchase agreement for the sale of non-voting convertible preferred stock (the “Preferred Stock”) in a private placement co-led by Affinity Asset Advisors, LLC and Ikarian Capital LLC with participation from other life science investors. The private placement closed on July 20, 2026 and resulted in gross proceeds of approximately $132.0 million.

 

●Announced the appointment of Lisa Pitt, Pharm.D., M.S.J. as Senior Vice President, Regulatory Affairs and Shiguang Liu, M.D., Ph.D. as Vice President, Clinical Development.

 

●Commenced an offer to purchase any and all of its outstanding warrants that were issued in its underwritten public offering on September 18, 2025. The purchase price was $9.72 in cash per warrant (post-reverse stock split).

 

○The Company has been advised that a total of 283,689 Warrants (post-reverse stock split) were properly tendered, which represents an aggregate cash payment of approximately $2.8 million. Following completion of the offer, 127,834 Warrants remain outstanding.

 

●In November 2026, Jasper effected a 1-for-30 reverse stock split (“Reverse Split”) of the Company’s common stock. Following the Reverse Split, there were approximately 1.1m shares of common stock issued and outstanding.

 

 

 

Third Quarter Fiscal 2026 Financial Results

 

●Cash and cash equivalents as of September 30, 2026, totaled $135.3 million.

 

●Research and development expense for the three months ended September 30, 2026, was $8.3 million.

 

●General and administrative expense for the three months ended September 30, 2026, was $6.4 million.

 

About Jasper

 

Jasper is a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases. The company is advancing a pipeline of medicines including vensobafusp alfa, briquilimab, and KP701. Vensobafusp alfa is a potential best-in-class dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other high unmet need nephrology disorders. Briquilimab is an anti-KIT antibody which has demonstrated positive clinical results both as a conditioning agent for stem cell transplant in severe combined immunodeficiencies (SCID), Fanconi anemia, as well as mast cell mediated diseases such as the chronic urticarias. KP701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders currently advancing to the clinic.

 

Forward-Looking Statements

 

Certain statements contained in this press release are or may be considered “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements can be identified by the fact that they do not relate strictly to historic or current facts. They use words such as “estimate,” “expect,” “intend,” “believe,” “plan,” “anticipate,” “potential,” “projected” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or condition. Jasper cautions that these statements are based upon the current beliefs and expectations of Jasper’s management and are subject to significant risks, uncertainties and assumptions, including, without limitation, risks related to the market price of Jasper’s common stock relative to the value suggested by the exchange ratio in connection with the merger; unexpected costs, charges or expenses resulting from the merger; potential adverse reactions or changes to business relationships resulting from the completion of the acquisition of Kira; the uncertainties associated with Jasper’s product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement, enrollment and completion of clinical trials and the timing of data readouts; risks related to the inability of Jasper to obtain sufficient additional capital to continue to advance product candidates and its preclinical programs; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; risks associated with the possible failure to realize certain anticipated benefits of the acquisition of Kira, including with respect to future financial and operating results; risks related to the integration of Kira and realization of anticipated benefits from the combination; risks related to the possibility that Jasper’s stockholders may not approve the conversion of the preferred stock and the consequences if such approval is not obtained, including potential obligations to settle preferred stock in cash; Jasper’s ability to maintain the listing of its common stock on the Nasdaq Capital Market; and such additional risks and uncertainties contained in the “Risk Factors” section of Jasper’s Annual Report on Form 10-K for the year ended December 31, 2025, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, and other Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that Jasper has subsequently filed or may subsequently file with the SEC. Statements regarding future actions, future performance and/or future results including, without limitation, those relating to the timing for completion, and results of, scheduled or additional clinical trials and the FDA’s or other regulatory review and/or approval and commercial launch and sales results (if any) of Jasper’s formulations and product candidates and regulatory filings related to the same, financial projections and targets, including, without limitation, cash runway, operating plans, future capital requirements and the sufficiency of existing cash resources, business strategy, plans and objectives for future operations, statements regarding Jasper and its operations and prospects, may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. There is no obligation to update publicly or revise any forward-looking statements for any reason after the date of this press release or to conform these statements to actual results or to changes in Jasper’s expectations, whether as a result of new information, future events, inaccuracies that become apparent after the date hereof or otherwise, except as may be required under applicable securities laws.

 

Contacts:

 

Alex Gray (investors)
Jasper Therapeutics
650-549-1454 
agray@jaspertx.com

 

Argot Partners (investors and media)

kira@argotpartners.com

 

2

 

 

JASPER THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except share and per share data)

(unaudited)

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2026   2025   2026   2025 
Revenue  $8,000   $—   $8,000   $— 
Costs and Expenses                    
Costs of drug supplies and compounds   7,993    —    7,993    — 
Research and development   8,327    14,391    19,276    51,744 
General and administrative   6,359    4,775    15,569    16,300 
Acquired in-process research and development   129,494    —    129,494    — 
Total operating expenses   152,173    19,166    172,332    68,044 
Loss from operations   (144,173)   (19,166)   (164,332)   (68,044)
Interest income   999    342    1,245    1,403 
Change in fair value of warrant liability   (1,240)   2,099    12,380    2,099 
Other income (expense), net   (41)   (2,011)   2,318    (2,158)
Total other income (expense), net   (282)   430    15,943    1,344 
Net loss and comprehensive loss  $(144,455)  $(18,736)  $(148,389)  $(66,700)
                     
Net loss per share attributable to common stockholders, basic and diluted  $(10.19)  $(32.08)  $(14.31)  $(125.30)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted   1,075,259    584,056    1,040,513    532,312 
Net loss per share attributable to non-voting redeemable convertible preferred stockholders, basic and diluted  $(13.97)  $—   $(13.97)  $— 
Weighted-average shares used in computing net loss per share attributable to non-voting redeemable convertible preferred stockholders, basic and diluted   9,555,390    -    9,555,390    - 

 

(1) Amounts include non-cash stock based compensation expense as follows (in thousands):

 

   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2026   2025   2026   2025 
                 
Research and development  $604   $486   $1,010   $1,600 
General and administrative   615    938    1,396    3,452 
Total  $1,219   $1,424   $2,406   $5,052 

 

3

 

 

JASPER THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(unaudited)

 

   September 30,   December 31, 
Assets  2026   2025 
Current assets:        
Cash and cash equivalents  $135,349   $28,692 
Restricted cash, current   417    - 
Accounts receivable   8,000    - 
Prepaid expenses and other current assets   3,508    5,953 
Total current assets   147,274    34,645 
Property and equipment, net   57    102 
Operating lease right-of-use assets   67    502 
Restricted cash, non-current   -    417 
Other non-current assets   18    113 
Total assets  $147,416   $35,779 
           
Liabilities, Non-voting Redeemable Convertible Preferred Stock and Stockholders’ Equity          
Current liabilities:          
Accounts payable  $3,759   $6,220 
Operating lease liabilities   69    1,235 
Accrued expenses and other current liabilities   10,084    5,745 
Total current liabilities   13,912    13,200 
Warrant liability   3,784    16,164 
CVR liability   1,900    - 
Other non-current liabilities   1,298    2,264 
Total liabilities   20,894    31,628 
           
Commitments and contingencies          
Non-voting redeemable convertible preferred stock   263,502    - 
Options for non-voting redeemable convertible preferred stock   3,267    - 
Stockholders’ equity          
Preferred stock   -    - 
Common stock   3    3 
Additional paid-in capital   324,809    320,818 
Accumulated deficit   (465,059)   (316,670)
Total stockholders’ equity   (140,247)   4,151 
Total liabilities, non-voting redeemable convertible preferred stock and stockholders’ equity  $147,416   $35,779 

 

4

 

Filing Exhibits & Attachments

4 documents

Keep reading